CoChat

Therapeutic landscape for Batten disease: current treatments and future prospects

Open access
Johnson, Tyler B., Cain, Jacob T., White, Katherine A., Ramirez-Montealegre, Denia, Pearce, David A., Weimer, Jill M. · 2019 · Nature Reviews Neurology
Cited by 187

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Batten disease (also known as neuronal ceroid lipofuscinoses) constitutes a family of devastating lysosomal storage disorders that collectively represent the most common inherited paediatric neurodegenerative disorders worldwide. Batten disease can result from mutations in 1 of 13 genes. These mutations lead to a group of diseases with loosely overlapping symptoms and pathology. Phenotypically, patients with Batten disease have visual impairment and blindness, cognitive and motor decline, seizures and premature death. Pathologically, Batten disease is characterized by lysosomal accumulation of autofluorescent storage material, glial reactivity and neuronal loss. Substantial progress has been made towards the development of effective therapies and treatments for the multiple forms of Batten disease. In 2017, cerliponase alfa (Brineura), a tripeptidyl peptidase enzyme replacement therapy, became the first globally approved treatment for CLN2 Batten disease. Here, we provide an overview of the promising therapeutic avenues for Batten disease, highlighting current FDA-approved clinical trials and prospective future treatments.In the past few years, substantial progress has been made towards effective treatment of Batten disease, a family of paediatric neurodegenerative lysosomal storage disorders. In this Review, the authors discuss new therapies for Batten disease, including cerliponase alfa, the first globally approved agent, and considers promising new therapeutic avenues for future treatments.Key pointsThe FDA approval of the enzyme replacement therapy cerliponase alfa (Brineura) for the treatment of CLN2 Batten disease is an important milestone in Batten disease therapy.Promising results from preclinical research indicate that gene therapy — particularly approaches that use adeno-associated virus — represents a promising treatment option for patients in the near future.Many of the preclinical strategies being explored for the treatment of one form of Batten disease could have applications across multiple subtypes of Batten disease and even other lysosomal storage disorders.Investigators now recognize that a single treatment might not be sufficient to halt disease progression and are exploring combinatorial approaches to tackle multiple aspects of Batten disease progression.A battery of new preclinical and clinical tools have been developed that facilitate effective therapy development in Batten disease, enabling an unprecedented acceleration in drug discovery for these fatal disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41582-019-0138-8

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 187

Metadata

Authors
Johnson, T. B., Cain, J. T., White, K. A., Ramirez-Montealegre, D., Pearce, D. A., & Weimer, J. M.
Venue
Nature Reviews Neurology
Published
2019-02-19
Volume
15
Issue
3
Pages
161-178
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W2916872745
Cited by
187
References
23
FWCI
4.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic landscape for Batten disease: current treatments and future prospects. https://app.cochat.ai/papers/10.1038/s41582-019-0138-8
The paper
Johnson, T. B., Cain, J. T., White, K. A., Ramirez-Montealegre, D., Pearce, D. A., & Weimer, J. M. (2019). Therapeutic landscape for Batten disease: current treatments and future prospects. Nature Reviews Neurology. https://doi.org/10.1038/s41582-019-0138-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.